Authors
Latest:
Dr D'Abreo on Patient Consideration When Choosing Treatments in HER2+ Breast CancerNina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.
Latest:
Palliative Care Can Address Gaps in Oncology LandscapePalliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.
Latest:
COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLLAt the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.
Latest:
Fox Chase Researchers Examine Alternative Methods of Specialized Imaging Scans for Kidney MassesFox Chase Researchers Examine Alternative Methods of Specialized Imaging Scans for Kidney Masses
Latest:
Dr. Ratan on the Steps of Diagnosing Desmoid TumorsRavin Ratan, MD, MEd, discusses the steps that should be taken to diagnose desmoid tumors.
Latest:
Dr Haffty on Technical and Biological Advancements in Radiotherapy Within Breast CancerBruce Haffty, MD, MS, discusses the significance of technical and biological advancements in approaches to radiotherapy, and how they engendered the de-escalation of radiotherapy for select patients with breast cancer.
Latest:
Immune Checkpoint Inhibitors Extend Survival for MesotheliomaImmune checkpoint inhibitor therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma.
Latest:
Dr. Zeidner on Transformation to AML in Higher-Risk MDSJoshua F. Zeidner, MD, discusses the risk of transformation to acute myeloid leukemia in higher-risk myelodysplastic syndromes.
Latest:
Dr Garje on Emerging Biomarkers in mCRPCRohan Garje, MD, discusses emerging biomarkers in metastatic castration-resistant prostate cancer and where the treatment field is headed.
Latest:
Comprehensive Treatment Advances Care for Patients With Early-Stage Breast CancerAdvances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.
Latest:
Dr Takvorian on the Evolution of PARP Inhibitors in Prostate CancerSamuel U. Takvorian, MD, MS, discusses the evolution of regulatory decisions regarding the use of PARP inhibitors for patients with prostate cancer.
Latest:
Dr. Patel on a Subgroup Analysis of the NAPOLI-1 Trial in Pancreatic CancerReema A. Patel, MD, discusses the results of a subgroup analysis from the NAPOLI-1 trial in pancreatic cancer.
Latest:
EGFR+ NSCLC: Advice for Community OncologistsA panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.
Latest:
Cabozantinib plus Atezolizumab in Locally Advanced/Metastatic Adrenocortical Carcinoma: Results From a Multi-Cohort Basket Phase II Trial (CABATEN/GETNE-T1914)Enrique Grande, MD, PhD, Msc, presents the results of a multi-cohort basket phase II trial, CABATEN/GETNE-T1914, evaluating cabozantinib plus atezolizumab in patients with locally advanced/metastatic adrenocortical carcinoma.
Latest:
Monitoring and Follow-Up of Patients with Chronic GVHDThe panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.
Latest:
Dr. Brenner on the Role of Trastuzumab Deruxtecan in Gastric CancerWarren S. Brenner, MD, discusses the utilization of fam-trastuzumab deruxtecan-nxki (Enhertu) as a HER2-directed therapy in gastric cancer.
Latest:
Dr Freeman on Factors Influencing Response to CAR T-Cell Therapy in HematologyCiara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.
Latest:
Discovering New Medicines in CancerOur ambition is to outsmart cancer by translating our science into health. The combination of our people and heritage is a particular advantage we have in achieving this goal. Our teams are curious, bold, and driven to deliver potentially transformative medicines to patients with cancer. Our heritage of science-based precision medicine and immuno-oncology means that we can branch into synergies to bridge different aspects of cancer research, in an agile and uncompromising manner. Our research focus is on three key mechanistic pillars: oncogenic pathways; immuno-oncology (IO); and DNA damage response (DDR); and, we are developing new approaches in key tumor types in GI, GU and thoracic cancers, all areas with significant unmet treatment needs. Together, we are transforming cancer care—today and tomorrow.
Latest:
Dr Coombs on the Ongoing Investigation of Quizartinib in AMLCatherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.
Latest:
Looking Toward the Future Management of Non–Small Cell Lung CancerClosing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.
Latest:
Dr. Van Rhee on the Clinical Implications of CAR T-Cell Therapy in Relapsed/Refractory MyelomaFrits van Rhee, MD, PhD, discusses the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.
Latest:
Prior EBRT Shows No Correlation With Hematologic Toxicity in Patients With mCRPC Treated With Ra-223Patients with mCRPC who received Ra-223 were not found to be at a higher relative risk of hematological toxicity if they had received prior EBRT.
Latest:
Dr. Janakiram on Future Targets and Strategies for CAR T-cell Therapy in MyelomaMurali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.
Latest:
Dr. Chauncey on Isatuximab Combinations in Multiple MyelomaThomas R. Chauncey, MD, PhD, discusses the phase 3 ICARIA-MM trial and IKEMA trials with isatuximab-irfc combinations in patients with relapsed or refractory multiple myeloma.
Latest:
Dr. Voorwerk on Rationale for Atezolizumab/Carboplatin in Metastatic Lobular Breast CancerLeonie Voorwerk, discusses the rationale for examining the combination of atezolizumab plus carboplatin in patients with metastatic lobular breast cancer.
Latest:
Neoadjuvant Darolutamide/ADT Followed By Radical Prostatectomy Is Safe/Effective in Localized Prostate CancerNeoadjuvant darolutamide with ADT followed by radical prostatectomy is safe and effective in patients with prostate cancer.
Latest:
Understanding Lynch Syndrome and Associated Cancer Risk: Future Preventive ConsiderationsIn this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.
Latest:
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian CancersMeghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.
Latest:
EGFR+ NSCLC: Advice for Community OncologistsA panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.
Latest:
Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma LandscapeMonoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.
%201%20(1)%20copy.jpg?fit=crop&auto=format)
